Surrozen, Inc./DE
SRZNNasdaq
$21.96
↑ +5.8%Jul 17 close · end-of-day
Price
1Y↑ +161.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$240,440.04
Enterprise Value
-$106.7M
P/E
—
P/S
0.0
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-14008.1%
Dividend Yield
—
Revenue (TTM)
$7.5M
Net Income (TTM)
-$342.6M
Free Cash Flow (TTM)
-$33.7M
Gross Margin
—
Operating Margin
-573.8%
Net Margin
-4571.1%
ROE
123.2%
ROIC
—
Debt / Equity
—
Net Cash
$106.9M
Return 1Y
+158.3%
Company profile
Surrozen, Inc. discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
- CEO
- Craig C. Parker
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- California
- Website
- https://www.surrozen.com/
Management & directors
- Li YangExec. Vice President, Research
- Maleki Andrew PedrumChief Financial Officer
- Parker Craig CChief Executive Officer
- Williams Charles OChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
SRZN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$5.0M↑ +408.6%
Diluted EPS-$11.65↑ +56.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $12.5M | $0.00 | $10.7M | $3.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$32.8M | -$54.4M | -$44.3M | -$45.8M | -$25.5M | -$42.1M |
| Net income | -$32.7M | -$54.6M | -$36.0M | -$43.0M | -$63.6M | -$242.0M |
| Diluted EPS | — | -$2.21 | -$15.56 | -$21.33 | -$21.67 | -$32.37 |
| Operating cash flow | -$29.1M | -$48.8M | -$44.1M | -$40.4M | -$17.6M | -$30.2M |
| Free cash flow | -$30.0M | -$50.1M | -$44.9M | -$40.8M | -$17.7M | -$30.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | -354.7% | — | -239.7% | -1210.6% |
| Net margin | — | — | -288.0% | — | -596.6% | -6960.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $10.0M | $655,000.00 | $983,000.00 | $983,000.00 | $983,000.00 | $528,000.00 | $5.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.0M | $1.2M | -$8.6M | -$9.6M | -$9.0M | -$10.9M | -$12.6M | -$10.5M |
| Net income | -$25.3M | -$1.4M | -$28.0M | -$27.0M | $39.7M | -$71.6M | -$183.2M | -$127.5M |
| Diluted EPS | -$7.99 | -$0.44 | -$9.00 | -$7.43 | $2.55 | -$8.36 | -$19.13 | -$11.65 |
| Operating cash flow | -$5.6M | -$6.8M | $3.5M | -$9.3M | -$6.1M | -$9.0M | -$5.8M | -$12.5M |
| Free cash flow | -$5.6M | -$6.8M | $3.5M | -$9.3M | -$6.1M | -$9.1M | -$5.9M | -$12.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | 12.3% | -1311.8% | -971.6% | -917.3% | -1107.3% | -2393.8% | -209.1% |
| Net margin | — | -14.3% | -4280.8% | -2743.6% | 4043.3% | -7288.2% | -34689.2% | -2550.1% |
Company news
May 17, 2026
Apr 28, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | Li Yang· Exec. Vice President, Research | Award | 1,666 | $8.11 | $13,511.26 | filing |
| 2026-06-15 | Williams Charles O· Chief Operating Officer | Award | 1,666 | $8.11 | $13,511.26 | filing |
| 2026-06-15 | Parker Craig C· Chief Executive Officer | Award | 1,622 | $8.11 | $13,154.42 | filing |
| 2026-06-15 | Maleki Andrew Pedrum· Chief Financial Officer | Award | 607 | $19.01 | $11,539.07 | filing |
| 2026-05-04 | Parker Craig C· Chief Executive Officer | Sale | 4,524 | $33.33 | $150,797.59 | filing |
| 2026-05-04 | Williams Charles O· Chief Operating Officer | Sale | 2,036 | $33.33 | $67,865.58 | filing |
| 2026-05-04 | Li Yang· Exec. Vice President, Research | Sale | 1,584 | $33.33 | $52,799.16 | filing |
| 2026-05-01 | Li Yang· Exec. Vice President, Research | Option exercise | 4,375 | — | — | filing |
| 2026-05-01 | Williams Charles O· Chief Operating Officer | Option exercise | 5,625 | — | — | filing |
| 2026-05-01 | Parker Craig C· Chief Executive Officer | Option exercise | 12,500 | — | — | filing |
| 2026-03-31 | Li Yang· Exec. Vice President, Research | Gift | 1,666 | $0.00 | $0.00 | filing |
| 2026-03-24 | TCG Crossover GP II, LLC | Buy | 53,329 | $24.69 | $1.3M | filing |
| 2026-03-24 | TCG Crossover GP II, LLC | Buy | 53,329 | $24.69 | $1.3M | filing |
| 2026-03-23 | TCG Crossover GP II, LLC | Buy | 7,612 | $24.90 | $189,538.04 | filing |
| 2026-03-23 | TCG Crossover GP II, LLC | Buy | 7,611 | $24.90 | $189,513.14 | filing |
| 2026-03-16 | TCG Crossover GP II, LLC | Buy | 595 | $24.99 | $14,866.49 | filing |
| 2026-03-16 | TCG Crossover GP II, LLC | Buy | 595 | $24.99 | $14,866.49 | filing |
| 2026-03-13 | TCG Crossover GP II, LLC | Buy | 17,717 | $24.88 | $440,744.04 | filing |
| 2026-03-13 | TCG Crossover GP II, LLC | Buy | 17,716 | $24.88 | $440,719.16 | filing |
| 2026-03-12 | TCG Crossover GP II, LLC | Buy | 6,187 | $24.99 | $154,582.81 | filing |
| 2026-03-12 | TCG Crossover GP II, LLC | Buy | 6,187 | $24.99 | $154,582.81 | filing |
| 2026-02-12 | TCG Crossover GP II, LLC | Buy | 547 | $23.86 | $13,052.79 | filing |
| 2026-02-12 | TCG Crossover GP II, LLC | Buy | 546 | $23.86 | $13,028.93 | filing |
| 2026-02-11 | TCG Crossover GP II, LLC | Buy | 8,882 | $23.58 | $209,393.15 | filing |
| 2026-02-11 | TCG Crossover GP II, LLC | Buy | 8,881 | $23.58 | $209,369.58 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.